Zonisade Suspension
Product Images NDC 52652-8001

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Zonisade (NDC 52652-8001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Azurity Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton-label-061722 (Zonisamide Oral Suspension Carton Label)

Carton-label-061722 (Zonisamide Oral Suspension Carton Label)
Carton label for ZONISADE (zonisamide) oral suspension, 100 mg/5 mL, 150 mL bottle, manufactured by Azurity Pharmaceuticals, Inc. The label includes dosing strength, route of administration (oral), storage and usage instructions, NDC 52652-8001-1, pharmacist dispensing information, and branding with the Azurity logo.*
FDA Label Image

Chemical Structure (Zonisamide Oral Suspension Chemical Stucture)

Chemical Structure (Zonisamide Oral Suspension Chemical Stucture)
Chemical structure of zonisamide, showing its molecular framework including a benzisoxazole ring and a sulfonamide group.*
FDA Label Image

Container-label-061722 (Zonisamide Oral Suspension Container Label)

Container-label-061722 (Zonisamide Oral Suspension Container Label)
Label for ZONISADE (zonisamide oral suspension) 100 mg/5 mL, 150 mL bottle by Azurity Pharmaceuticals, Inc. The label includes storage instructions, a dosing note to see prescribing information, pharmacist dispensing instructions with a URL, and space for lot and expiration dates. The product is for oral use only and requires shaking before use.*
FDA Label Image

Figure 1 (Zonisamide Oral Suspension Figure 1)

Figure 1 (Zonisamide Oral Suspension Figure 1)
A percent reduction in all partial seizure rate chart comparing Zonisamide to placebo. The x-axis represents the percent of patients, and the y-axis shows the percent reduction in seizure rate, with direction arrows indicating improvement and worsening. The graph plots two treatment arms: Zonisamide (blue dots) and placebo (orange diamonds), illustrating different efficacy outcomes across patient percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.